How to avoid future Vioxx-type scandals

Prescrire Int. 2005 Jun;14(77):115-7.

Abstract

The market withdrawal of rofecoxib (Vioxx) in September 2004 was the logical, if long-overdue, result of what has become a major scandal. How can similar situations be avoided in the future? The authorities must of course come to grips with their responsibilities, but caregivers, patients and journalists also have a role to play. This was the theme of the press conference held at Prescrire headquarters after the annual awards ceremony on 20 January 2005

MeSH terms

  • Cardiovascular Diseases / chemically induced*
  • Clinical Trials as Topic
  • Conflict of Interest
  • Disclosure
  • Drug Approval*
  • Drug Industry*
  • France
  • Government Regulation*
  • Humans
  • Journalism
  • Lactones / adverse effects*
  • Osteoarthritis / drug therapy
  • Product Surveillance, Postmarketing
  • Sulfones / adverse effects*
  • United States
  • United States Food and Drug Administration

Substances

  • Lactones
  • Sulfones